Abstract
Mass spectrometry biomarker discovery may assist patients diagnosis in time and realize the characteristics of new diseases. Our previous work built a preprocess method called HHTmass which is capable of removing noise, but HHTmass only a proof of principle to be peak detectable and did not tested for peak reappearance rate and used on medical data. We developed a modified version of biomarker discovery method called Enhance HHTMass (E-HHTMass) for MALDI-TOF and SELDI-TOF mass spectrometry data which improved old HHTMass method by removing the interpolation and the biomarker discovery process. E-HHTMass integrates the preprocessing and classification functions to identify significant peaks. The results show that most known biomarker can be found and high peak appearance rate achieved comparing to MSCAP and old HHTMass2. E-HHTMass is able to adapt to spectra with a small increasing interval. In addition, new peaks are detected which can be potential biomarker after further validation.
Keywords: Biomarker discovery, Hilbert-Huang transform, MALDI-TOF, Mass spectrometry, SELDI-TOF, HHTmass, MASCAP, Nephrological disease, Urinary hepcidin, Oral cancer:, SpecAlign, Denoising, WEKA, GUI
Protein & Peptide Letters
Title: Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform
Volume: 19 Issue: 1
Author(s): Li-Ching Wu, Ping-Heng Hsieh, Jorng-Tzong Horng, Yu-Jen Jou, Chia-Der Lin, Kuang-Fu Cheng, Cheng-Wen Lin and Shih-Yin Chen
Affiliation:
Keywords: Biomarker discovery, Hilbert-Huang transform, MALDI-TOF, Mass spectrometry, SELDI-TOF, HHTmass, MASCAP, Nephrological disease, Urinary hepcidin, Oral cancer:, SpecAlign, Denoising, WEKA, GUI
Abstract: Mass spectrometry biomarker discovery may assist patients diagnosis in time and realize the characteristics of new diseases. Our previous work built a preprocess method called HHTmass which is capable of removing noise, but HHTmass only a proof of principle to be peak detectable and did not tested for peak reappearance rate and used on medical data. We developed a modified version of biomarker discovery method called Enhance HHTMass (E-HHTMass) for MALDI-TOF and SELDI-TOF mass spectrometry data which improved old HHTMass method by removing the interpolation and the biomarker discovery process. E-HHTMass integrates the preprocessing and classification functions to identify significant peaks. The results show that most known biomarker can be found and high peak appearance rate achieved comparing to MSCAP and old HHTMass2. E-HHTMass is able to adapt to spectra with a small increasing interval. In addition, new peaks are detected which can be potential biomarker after further validation.
Export Options
About this article
Cite this article as:
Wu Li-Ching, Hsieh Ping-Heng, Horng Jorng-Tzong, Jou Yu-Jen, Lin Chia-Der, Cheng Kuang-Fu, Lin Cheng-Wen and Chen Shih-Yin, Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform, Protein & Peptide Letters 2012; 19 (1) . https://dx.doi.org/10.2174/092986612798472929
DOI https://dx.doi.org/10.2174/092986612798472929 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Functional Scaffold in Marine Alkaloid: An Anticancer Moiety for Human
Current Medicinal Chemistry Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy
Mini-Reviews in Medicinal Chemistry Endocrine and Antineoplastic Actions of Growth Hormone-Releasing Hormone Antagonists
Current Medicinal Chemistry Multifunctional Nanomedicine Platform for Cancer Specific Delivery of siRNA by Superparamagnetic Iron Oxide Nanoparticles-Dendrimer Complexes
Current Drug Delivery Cell Division Cycle 25 (Cdc25) Phosphatase Inhibitors as Antitumor Agents
Drug Design Reviews - Online (Discontinued) A Review on Missing Value Imputation Algorithms for Microarray Gene Expression Data
Current Bioinformatics Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Drug Targeting of Estrogen Receptor Signaling in the Cardiovascular System: Preclinical and Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy
Current Drug Targets Meta-heuristic Techniques to Train Artificial Neural Networks for Medical Image Classification: A Review
Recent Advances in Computer Science and Communications Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry The Medicinal Chemistry of Therapeutic Peptides: Recent Developments in Synthesis and Design Optimizations
Current Medicinal Chemistry Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry Evaluation and Management of Adnexal Masses in Postmenopausal Women
Current Women`s Health Reviews Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Novel Agents in Anticancer Drug Therapy I (Antiangiogenic Agents, Egfr Inhibitors)
Medicinal Chemistry Reviews - Online (Discontinued) Modulation of pRb/E2F Functions in the Regulation of Cell Cycle and in Cancer
Current Cancer Drug Targets